Cargando…

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors

Patients with malignant peripheral nerve sheath tumor (MPNST), a rare soft tissue cancer associated with loss of the tumor suppressor neurofibromin (NF1), have poor prognosis and typically respond poorly to adjuvant therapy. We evaluated the effect of 299 clinical and investigational compounds on se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolberg, Matthias, Bruun, Jarle, Murumägi, Astrid, Mpindi, John P., Bergsland, Christian H., Høland, Maren, Eilertsen, Ina A., Danielsen, Stine A., Kallioniemi, Olli, Lothe, Ragnhild A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579334/ https://www.ncbi.nlm.nih.gov/pubmed/28556483 http://dx.doi.org/10.1002/1878-0261.12086

Ejemplares similares

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
por: Danielsen, Stine A., et al.
Publicado: (2015)

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
por: Bruun, Jarle, et al.
Publicado: (2018)

Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
por: Kolberg, Matthias, et al.
Publicado: (2013)

Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
por: Høland, Maren, et al.
Publicado: (2023)

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
por: Bruun, Jarle, et al.
Publicado: (2021)

Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
por: Berg, Kaja C. G., et al.
Publicado: (2019)

Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours – A prognostic test after surgical resection
por: Kolberg, Matthias, et al.
Publicado: (2015)

Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series
por: Bruun, Jarle, et al.
Publicado: (2014)

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
por: Berg, Kaja C. G., et al.
Publicado: (2017)

Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer
por: Bergsland, Christian H., et al.
Publicado: (2022)

CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
por: Eide, Peter W., et al.
Publicado: (2017)

Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2
por: Lopes, Nair, et al.
Publicado: (2019)

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Kohtamäki, Laura, et al.
Publicado: (2021)

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
por: Smeby, Jørgen, et al.
Publicado: (2020)

Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell‐intrinsic properties
por: Eide, Peter W., et al.
Publicado: (2019)

High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
por: Hongisto, Vesa, et al.
Publicado: (2013)

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
por: Kangaspeska, Sara, et al.
Publicado: (2016)

Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma
por: Nordberg, Janne, et al.
Publicado: (2012)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs
por: Khan, Suleiman A, et al.
Publicado: (2012)

High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer
por: Vainio, Paula, et al.
Publicado: (2012)

The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021)

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
por: Bergsland, Christian H, et al.
Publicado: (2020)

A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses
por: Härmä, Ville, et al.
Publicado: (2010)

Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
por: Eilertsen, Ina A., et al.
Publicado: (2018)

Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms
por: Kangaspeska, Sara, et al.
Publicado: (2012)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2018)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1
por: Sveen, Anita, et al.
Publicado: (2017)

Novel Genomic Aberrations in Testicular Germ Cell Tumors by Array-CGH, and Associated Gene Expression Changes
por: Skotheim, Rolf I., et al.
Publicado: (2006)

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion
por: Lehtinen, Laura, et al.
Publicado: (2012)

Correction: Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage
por: Glaire, Mark A., et al.
Publicado: (2019)

Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage
por: Glaire, Mark A., et al.
Publicado: (2019)

Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells
por: Ketola, Kirsi, et al.
Publicado: (2012)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Phospholipase C Isozymes Are Deregulated in Colorectal Cancer – Insights Gained from Gene Set Enrichment Analysis of the Transcriptome
por: Danielsen, Stine A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vvrmlorscculh5m9080i535aon